Sinopharm Tech Holdings Limited issued its monthly return for the period ended 31 March 2026, indicating that no changes occurred in either authorised or issued share capital during the month.

Authorised Capital • The aggregate authorised capital remained at HKD 200.00 million, divided into 12.80 billion ordinary shares and 3.20 billion non-voting convertible preference shares, both with a par value of HKD 0.0125.

Issued Shares • Ordinary shares in issue stood unchanged at 633.69 million, with no treasury shares on record. • Outstanding non-voting convertible preference shares were stable at 1.48 billion, representing a notional amount of HKD 148.02 million and convertible into ordinary shares on a 1:1 basis at HKD 0.10 per share. No conversions took place during the month.

Public Float • The company confirmed compliance with the minimum 25 % public-float requirement for its ordinary shares as at 31 March 2026.

Share-based Instruments • Under the 2021 Share Option Scheme, 5.08 million options remained outstanding with an adjusted exercise price of HKD 1.00. These options could generate up to 5.08 million new ordinary shares, while an additional 12.30 million shares remain available for future grants under the scheme. No options were exercised, lapsed, or cancelled in March.

Liquidity Events • The report recorded no share repurchases, cancellations, redemptions, or treasury share transfers. Likewise, no new warrants, additional convertibles, or other equity instruments were issued.

Overall, Sinopharm Tech’s capital structure and share counts were unchanged throughout March 2026, maintaining a stable equity position and meeting all listing-rule obligations.